Abstract：Primary hepatic carcinoma（PHC）is the second leading cancer that caused death in the world. The morbidity of PHC is increasing year by year,which threaten people's lives and health. Chronic hepatitis B is considered to be an independent risk factor for PHC,and the incidence of PHC is higher in patients who have progressed to liver cirrhosis. We reviewed the domestic and abroad literatures about the risk factors for hepatitis B cirrhosis progressing to PHC from the year of 1992 to 2018,and concluded that HBV-DNA,HBsAg,HBeAg expression,antiviral treatment time,different antiviral drugs,degree of cirrhosis,alanine transaminase and family history were related to the development of PHC from cirrhosis.
[1] LLOVET J M,ZUCMAN R J,PIKARSKY E,et al.Hepatocellular carcinoma[J].Nat Rev Dis Primers,2016,2(16018):123. [2] 朱笑生,刘文超. 原发性肝癌全球流行情况和危险因素的新进展[J]. 现代肿瘤医学,2018,26(14):2297-2301. [3] EL-SERAG H B. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology,2012,142(6):1264-1273. [4] RINGELHAN M,O'CONNOR T,PROTZER U,et al. The direct and indirect roles of HBV in liver cancer:prospective markers for HCC screening and potential therapeutic targets[J]. J Pathol, 2015,235(2):355-367. [5] YIN J,LI N,HAN Y,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study[J]. J Clin Oncol,2013,31(29):3647-3655. [6] KWON J H,CHOI J Y,JANG J W,et al.Impact of serial hepatitis B Virus DNA on hepatocellular carcinoma development in patients with liver cirrhosis[J]. Intervirology,2010,53(2):111-118. [7] LIN C W,LIN C C,MO L R,et al.Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis[J]. J Hepatol,2013,58(4):730-735. [8] ZHANG W,WANG X,WANG Y,et al.Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B:results of a 10-year follow up[J]. Medicine,2017,96(44):e8454. [9] LUCIFORA J,XIA Y,REISINGER F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science,2014,343(6176):1221-1228. [10] CHIEN J,LIU J,LEE M,et al.Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis[J]. Journal of Gastroenterology and Hepatology,2016, 31(12):7. [11] 谢龚峰,迟晶. 乙型肝炎病毒表面抗原定量与肝癌的关系探讨[J]. 胃肠病学和肝病学杂志,2013,22(8):812-814. [12] 曾达武,董菁,陈丽红,等. 免疫清除期慢性乙型肝炎患者血清HBsAg水平与肝组织炎症分级及纤维化分期的关系[J]. 中华肝脏病杂志,2012,20(10):746-750. [13] 杨柳青,林国莉,吴元凯,等.乙型肝炎肝硬化患者核苷(酸)类药物治疗期间新发肝癌的危险因素分析[J]. 中华临床感染病杂志,2012,5(1):28-32. [14] 高蕊,刘中景,陈菲,等. 乙型肝炎相关性原发性肝癌相关危险因素的Logistic回归分析[J]. 临床肝胆病杂志,2014,30(4):370-372. [15] KUROKAWA M,HIRAMATSU N,OZE T.Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection[J]. J Gastroenterol,2012,47(5):577-585. [16] KATO I,TOMINAGA S,IKARI A.The risk and predictive factors for developing liver cancer among patients with decompensated liver cirrhosis[J]. Japanese Journal of Clinical Oncology,1992,22(4):278-285. [17] TREPO C,CHAN H L,LOK A.Hepatitis B virus infection[J]. Lancet,2014(384):2053-2063. [18] LEE J,SINN D H,KIM J H,et al.Hepatocellular carcinoma risk of compensated cirrhosis patients with elevated hbv dna levels according to serum aminotransferase levels[J]. Journal of Korean Medical Science,2015,30(11):1618-1624. [19] SINN D H,LEE J,GOO J,et al.Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load[J]. Hepatology,2015,62(3):694-701. [20] TERRAULT N A,LOK A S,MCMAHON B J,et al.Update on prevention,diagnosis,and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599. [21] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398. [22] LEE J I,KIM Y S,et al.KASL clinical practice guidelines:management of hepatitis B[J]. Clinical and molecular hepatology,2016,22(1):76-139. [23] DELANEY W E.Progress in the treatment of chronic hepatitis B:long-term experience with adefovir dipivoxil[J]. Journal of Antimicrob Chemother,2007,59(5):827-832. [24] ZHANG Q Q,AN X,LIU Y H,et al.Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications:a meta-analysis[J]. Journal of Hepatology,2011,8(1):1-11. [25] SUN J,LI Y E,WANG Y N,et al.Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of chronic hepatitis B patients with compensated cirrhosis:a retrospective cohort study[J]. Infectious Agents and Cancer,2018,13(1):17. [26] LIM Y S,HAN S,HEO N Y,et al.Mortality,liver transplantation,and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavirvs lamivudine[J]. Gastroenterology,2014,147(1):152-161. [27] COMELL R C,GREENWAY H T,TUCKER S B,et al.Intralesional inter feron therapy for basal cell carcinoma[J]. J Am Acad Dermatol,1990,23(4):694-700. [28] BONINO F,OLIVERI F,COLOMBATTO P,et al.Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis:results of an international survey[J]. Journal of Viral Hepatitis,1997,4(S2):79-82. [29] HUANG K W,HUANG Y C,TAI K F,et al.Dual therapeutic effects of Interferon-α gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis[J]. Molecular Therapy,2008,16(10):1681-1687. [30] SHIM J J,OH C H,KIM J W,et al.Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy[J]. Scandinavian Journal of Gastroenterology,2017,52(9):1-8. [31] 邵帅. 血清前白蛋白、总胆汁酸、凝血指标、血小板参数联合检测在肝硬化患者中的相关性分析[J]. 中国医药指南,2017,15(19):114. [32] BRICHLER S,NAHON P,ZOULIM F,et al.Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis:results of ANRS CO12 CirVir cohort[J]. J Viral Hepat,2019:1-13. [33] KIM E J,YEON J E,KWON O S,et al.Rapid alanine aminotransferase normalization with entecavir and hepatocellular carcinoma in hepatitis B virus-associated cirrhosis[J]. Digestive Diseases and Sciences,2017,62(3):808-816. [34] ZECHINI B,PASQUAZZI C,ACETI A.Correlation of serum aminotranserases with HCV RNA levels and histological findings in patients with chronic hepatitis C:the role of serum aspartate transaminase in the evaluation of disease progression[J]. Eur J Gastroenterol Hepatol,2004,16(9):891-896. [35] YANG H I,YEH S H,CHEN P J,et al.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma[J]. J Natl Cancer Inst,2008(100):1134-1143. [36] SINGAL A K,SALAMEH H,KUO Y F,et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J]. Aliment Pharmacol Ther,2013(38):98-106. [37] CHEN C F,LEE W C,YANG H I,et al.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J]. Gastroenterology,2011(141):1240-1248. [38] TURATI F,EDEFONTI V,TALAMINI R,et al.Family history of liver cancer and hepatocellular carcinoma[J]. Hepatology,2012, 55(5):1416-1425. [39] LI Y,ZHANG Z,SHI J,et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China[J]. Int J Clin Exp Med,2015,8(1):1205-1212. [40] 张原青,彭利军,曹忆嵘,等.慢性乙型肝炎肝硬化患者发生肝细胞癌的危险因素分析[J].中华肝脏病杂志,2015,23(7):512-516. [41] 谭盛葵,仇小强. 原发性肝癌危险因素研究新进展[J]. 现代预防医学,2007,34(5):844-849.
